肿瘤细胞治疗研究
英文原题：Adoptive T-cell therapy for Hodgkin lymphoma.
尽管CAR T细胞疗法已获美国食品药品监督管理局批准用于B细胞非霍奇金淋巴瘤，但用于治疗经典霍奇金淋巴瘤（cHL）的过继性免疫疗法的发展并未以类似的速度加快。
尽管CAR T细胞疗法已获美国食品药品监督管理局批准用于B细胞非霍奇金淋巴瘤，但用于治疗经典霍奇金淋巴瘤（cHL）的过继免疫疗法的发展并未以类似速度推进。使用EB病毒特异性细胞毒性T淋巴细胞和CD30 CAR T细胞的过继T细胞疗法，已在cHL患者的早期临床试验中显示出显著的临床缓解。此外，靶向cHL中免疫抑制性肿瘤微环境的CD19和CD123 CAR T细胞也已被研究。在此，我们讨论cHL患者过继免疫疗法的临床试验概况，并着眼于当前挑战以及改善cHL CAR T细胞疗法开发的新策略。
Although CAR T-cell therapy is US Food and Drug Administration-approved for B-cell non-Hodgkin lymphomas, the development of adoptive immunotherapy for the treatment of classic Hodgkin lymphoma (cHL) has not accelerated at a similar pace. Adoptive T-cell therapy with Epstein-Barr virus-specific cytotoxic T lymphocytes and CD30 CAR T cells have demonstrated significant clinical responses in early clinical trials of patients with cHL. Additionally, CD19 and CD123 CAR T cells that target the immunosuppressive tumor microenvironment in cHL have also been investigated. Here we discuss the landscape of clinical trials of adoptive immunotherapy for patients with cHL with a view toward current challenges and novel strategies to improve the development of CAR T-cell therapy for cHL.
MEMBER ACCOUNT
登录成功会直接打开下一页。
